10-Q: Protagenic Therapeutics Faces Financial Strain, Delisting Concerns

Protagenic Therapeutics reports a significant net loss and working capital deficit for Q2 2026, highlighting ongoing financial challenges and the need for additional capital.

Summary

• Protagenic Therapeutics reported a net loss of $963,616 for the three months ended June 30, 2026, compared to a net loss of $5,057,523 for the same period in 2025.
• Total operating expenses decreased by 20% to $961,247 for Q2 2026 from $1,208,374 in Q2 2025, primarily due to a reduction in Research and Development expenses.
• The company had cash of $565,985 and a working capital deficit of $362,743 as of June 30, 2026.
• Management believes the company's current cash position is insufficient to fund operations past the end of the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern.
• The company's common stock was delisted from the Nasdaq Capital Market effective January 5, 2026, and is now quoted on the OTCQB.
• The company is actively exploring strategic and financing alternatives, including potential corporate transactions and partnerships.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant ongoing losses, a working capital deficit, and substantial doubt about the company's ability to continue as a going concern, despite some operational expense reductions.

Positives

• Operating expenses decreased by 20% to $961,247 in Q2 2026 from $1,208,374 in Q2 2025.
• Research and Development expenses decreased significantly by 72% to $109,925 in Q2 2026 from $394,112 in Q2 2025.
• Consulting fees increased by 82% to $284,542 in Q2 2026 from $156,760 in Q2 2025, potentially indicating increased strategic activity or external support.
• The company has two full-time employees and three paid consultants, indicating a lean operational structure.

Negatives

• The company incurred a net loss of $963,616 for the three months ended June 30, 2026.
• As of June 30, 2026, the company had a working capital deficit of $362,743.
• The company has an accumulated deficit of $4,993,245 as of June 30, 2026.
• Cash and cash equivalents decreased to $565,985 as of June 30, 2026, from $1,509,178 as of March 31, 2026.
• The company's cash resources are projected to be insufficient to fund operations past the end of the third quarter of 2026.
• There are substantial doubts about the company's ability to continue as a going concern within one year.
• The company's common stock was delisted from the Nasdaq Capital Market and is now quoted on the OTCQB.
• Material weaknesses in internal control over financial reporting were identified, including a lack of adequate segregation of duties and limited multiple reviews in the financial reporting process.

Risks

• The company has incurred recurring losses and negative cash flows from operations and expects to continue to do so, raising substantial doubt about its ability to continue as a going concern.
• The company's cash resources are not sufficient to fund its operations past approximately the end of the third quarter of 2026, and additional capital may be required.
• There is no assurance that efforts to raise additional capital or enter into strategic transactions will be successful on acceptable terms.
• The company's common stock was delisted from the Nasdaq Capital Market and is now quoted on the OTCQB, which may affect liquidity and investor interest.
• Material weaknesses in internal control over financial reporting could lead to a material misstatement in financial statements.
• The company's lead drug candidate, PT00014, is still in early development, and FDA approval is not anticipated until 2029, if at all.
• The company is involved in a legal pursuit of at least $643,253 from its former contract research organization, Axiom Real-Time Metrics Inc., but recovery is not forecasted.

Future Outlook

The company anticipates continued losses and negative cash flows from operations for the foreseeable future. Management believes its current cash position is insufficient to fund operations past the end of the third quarter of 2026, necessitating the raising of additional capital. The company is exploring strategic and financing alternatives, including partnerships and royalty-based financing. FDA approval for its lead drug candidate is not anticipated before 2029.

Management Comments

• Management believes the Company has multiple potential avenues to raise additional capital, including the equity markets, and that its current cash position, together with its continued ability to manage the timing and level of operating expenditures, supports near-term operations while it pursues those alternatives.
• The Company is actively exploring strategic and financing alternatives, including possible corporate transactions involving a partnership for its lead program, royalty-based financing arrangements, and other business development opportunities.
• The Company has also received an unsolicited inquiry regarding a potential partnership from an established company with expertise in neurobiology and is broadening its outreach to additional potential partnership candidates.
• Management does not know whether additional financing will be on terms favorable or acceptable to us when needed, if at all.
• If adequate additional funds are not available when required, or if we are unsuccessful in entering into partnership agreements for further development of our product candidates, management may need to curtail its development efforts and planned operations.

Industry Context

StockSavvy.ai notes that Protagenic Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, where significant investment is required for drug development and regulatory approval. The company's focus on stress-related neuropsychiatric and mood disorders addresses a significant unmet medical need, but the long development timelines and high failure rates are characteristic of the industry.

Comparison to Industry Standards

• The company's net loss of $963,616 for the quarter is substantial for a development-stage biopharmaceutical company, but the reduction from the prior year's loss of $5,057,523 is a positive step.
• The significant decrease in R&D expenses (72%) may indicate a shift in development strategy or a slowdown in clinical trial progress, which could be viewed negatively compared to peers actively advancing multiple candidates.
• The company's cash burn rate of approximately $944,298 per quarter, coupled with a cash balance of $565,985, suggests a critical need for immediate financing, a common challenge for many early-stage biotechs.
• The delisting from Nasdaq and subsequent trading on OTCQB is a significant negative indicator compared to industry peers that maintain listings on major exchanges, potentially impacting access to capital and investor confidence.

Corporate Governance

Legal Proceedings

• The company filed a complaint against its former contract research organization, Axiom Real-Time Metrics Inc., seeking remuneration for pre-paid services not rendered, but recovery is not forecasted as Axiom has filed for receivership.

Related Party Transactions

• During the three months ended June 30, 2025, related parties made non-interest bearing advances to the Company totaling $77,756.
• The Company receives free office space from its Executive Chairman, Dr. Armen.
• During the year ended March 31, 2026, the Company engaged Agenus Inc. (a related party due to director overlap) for R&D services, incurring no expenses or outstanding amounts.

Stakeholder Impact

• Shareholders face continued financial uncertainty, potential dilution from future capital raises, and the risk of further share price decline due to delisting and going concern issues.
• Creditors and suppliers may face increased risk of delayed payments due to the company's liquidity challenges.
• Employees may experience job insecurity given the company's precarious financial situation and the need for potential operational curtailment.

Next Steps

• Commence multiple dose portion of Phase Ib study for PT00114 in Q4 2026.
• Initiate Phase IIa study for PT00114 in Q2 2027.
• Make Phase IIa study results for PT00114 publicly available in Q3 2027.
• Continue to explore strategic and financing alternatives to secure additional capital.
• Implement enhanced controls and procedures to address material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company exhibits significant financial distress, including substantial losses, a working capital deficit, and substantial doubt about its ability to continue as a going concern. The delisting from Nasdaq further exacerbates liquidity and investor confidence issues. While there are ongoing development efforts, the long timeline to potential revenue and the immediate financial challenges make the stock a high-risk investment, warranting a sell recommendation.

Keywords

biopharmaceutical, drug development, neuropsychiatric disorders, clinical trials, going concern, delisting, OTC, capital raise